ABBV — AbbVie Inc.

AbbVie Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Adjusted Earnings Per Share (EPS): $2.65, exceeding guidance by $0.07.
• Total Net Revenues: $15 billion, beating expectations by $300 million, reflecting a 12.4% year-over-year growth.
• Adjusted Gross Margin: 83.6% of sales.
• Adjusted R&D Expense: 15.1% of sales; Adjusted SG&A Expense: 22.7% of sales.
• Adjusted Operating Margin: 40.8% of sales, impacted by acquired IPR&D expenses.
• Net Interest Expense: $645 million; Adjusted Tax Rate: 15.4%.

2. Strategic Updates and Business Highlights

• AbbVie is raising its full-year adjusted EPS guidance to between $14.08 and $14.28.
• Key growth drivers include:
  • Immunology: Skyrizi sales reached $4.5 billion (up 29.2%), with strong performance in psoriatic disease and IBD. Rinvoq also performed well, generating $2.1 billion (up 20.2%).
  • Neuroscience: Revenues of nearly $2.9 billion (up 24.3%), driven by strong sales of Vraylar and Botox.
  • Oncology: Revenues over $1.6 billion, with Venclexta sales at $770 million (up 9.7%).
  • Aesthetics: Sales of nearly $1.2 billion (up 5.1%), with Botox performing well.
• Significant investments in R&D and manufacturing, including a $1.4 billion campus in North Carolina and $380 million for new plants in North Chicago.

3. Forward Guidance and Outlook

• Full-year net revenue forecast raised to approximately $67.3 billion.
• Anticipated global revenues for Skyrizi at $21.6 billion and Rinvoq at $10.2 billion.
• Expected adjusted operating margin ratio of approximately 47.5%.
• Second-quarter revenue forecast of approximately $16.7 billion, with adjusted EPS between $3.74 and $3.78.

4. Bad News, Challenges, or Points of Concern

• HUMIRA Sales Decline: HUMIRA sales fell to $688 million, down 40.3% due to biosimilar competition.
• Competitive Pressures: Concerns about new entrants in the immunology space, particularly with oral therapies. AbbVie is preparing for increased competition but remains confident in Skyrizi's positioning.
• Aesthetics Market Dynamics: The aesthetics business is facing headwinds from economic pressures, with Botox and Juvederm showing mixed performance.
• Regulatory Delays: A complete response letter was received for an aesthetics product, indicating potential delays in approvals.

5. Notable Q&A Insights

• Competitive Landscape for Skyrizi: AbbVie is confident in Skyrizi's superiority data and market positioning despite emerging oral competitors.
• Rinvoq's Future: There is optimism about Rinvoq's potential in new indications like alopecia areata and vitiligo, with expectations of exceeding previous revenue estimates.
• Tavapadon in Parkinson's: Positioned as a potential blockbuster, it is expected to complement existing therapies and address younger patient demographics.
• M&A Strategy: AbbVie remains open to acquiring external innovations, particularly in neuroscience, oncology, and obesity, to bolster its pipeline and growth prospects.

Overall, AbbVie demonstrated strong financial performance in Q1 2026, with robust growth across its portfolio, strategic investments in R&D, and an optimistic outlook despite facing competitive pressures and market challenges.